# Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

> **NCT04563299** · PHASE4 · TERMINATED · sponsor: **Retina Vitreous Associates of Florida** · enrollment: 10 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** Dextenza 0.4Mg Ophthalmic Insert
- **DRUG:** Prednisolone Acetate

## Key facts

- **NCT ID:** NCT04563299
- **Lead sponsor:** Retina Vitreous Associates of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-09
- **Primary completion:** 2023-02-14
- **Final completion:** 2023-02-14
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Subject Enrollment
- **Last updated:** 2023-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563299, "Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04563299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*